BackgroundCheck.run
Search For

Hongjun Jun Zhang254 Park St, Boston, MA 02132

Related to:
Jimmy C Yu 51 Guowei Zhang

Hongjun Zhang Phones & Addresses

254 Park St, West Roxbury, MA 02132   

Boston, MA   

Newton, MA   

San Diego, CA   

Atlanta, GA   

Poway, CA   

La Jolla, CA   

Work

Company: Holland & Knight LLP Address:
Get Report
Control this profile

Mentions for Hongjun Jun Zhang

Career records & work history

Lawyers & Attorneys

Hongjun Zhang Photo 1

Hongjun Zhang - Lawyer

Office:
Holland & Knight LLP
Specialties:
Environment, China, International and Cross Border Transactions, International Practices
ISLN:
918086363
Admitted:
2003
University:
Peking University, B.S., 1986; Peking University, M.S.; Peking University, Ph.D.
Law School:
Harvard Law School, LL.M., 2000

Hongjun Zhang resumes & CV records

Resumes

Hongjun Zhang Photo 18

Director Of Medicinal Chemistry

Location:
Boston, MA
Industry:
Pharmaceuticals
Work:
Cerevel Therapeutics
Director of Medicinal Chemistry Merck
Associate Principal Scientist--Medicinal Chemistry Merck May 2009 - May 2014
Senior Scientist--Medicinal Chemistry The Scripps Research Institute Nov 2006 - Apr 2009
Postdoctoral Research Associate Emory University Aug 2002 - Oct 2006
Graduate Student Shanghai Institute of Organic Chemistry Jul 1999 - May 2002
Reseach Associate
Education:
Emory University 2002 - 2006
Doctorates, Doctor of Philosophy, Philosophy, Organic Chemistry Fudan University 1996 - 1999
Master of Science, Masters, Chemistry Fudan University 1991 - 1996
Bachelors, Bachelor of Science, Chemistry
Skills:
Medicinal Chemistry, Organic Chemistry, Drug Discovery, Chemistry, Organic Synthesis, Total Synthesis, Natural Products, Small Molecules, Lifesciences, Technology Transfer, Gpcrs, Nmr, Cro, Drug Design, Lc Ms, Immunology
Languages:
Mandarin
English
Hongjun Zhang Photo 19

Hongjun Zhang

Hongjun Zhang Photo 20

Hongjun Zhang

Work:
LC-1 in Shanghai Institute of Cell Biology 1995 to 1996 Department of Biology of Wuhan University 1987 to 1989
Education:
University of Southern California - Post, California, US 2007 to 2012
doctoral in biology University of Southern California - Post, California, US 2002 to 2006
doctoral in Molecular biology University of Southern California 1994 to 1997
Ph.D. in microbiology and immunology Shanghai Institute of Cell Biology 1989 to 1993
Master of Science in Immunology Wuhan University in China 1985 to 1989
Bachelor of Science in Biology
Hongjun Zhang Photo 21

Hongjun Zhang

Work:
Molecular team in Manufacturing Department 2013 to 2000
Manufacturing Associate II Chemistry 2009 to 2014 NMR Studies of the Dynamics of Nitrophorin 2013 to 2013 University of Arizona 2002 to 2013
Research Specialist Ligand Binding Modes and Electronic Properties 2012 to 2012 Shokhireva TK, Berry RE, Zhang H, Shokhirev NV, Walker FA 2011 to 2011 Journal of Biological Inorganic Chemistry 2010 to 2010 Intermediates and Their Role 2010 to 2010 Protein Expression and Purification 2007 to 2007 Shokhirev NV 2007 to 2007 Biochemistry 2007 to 2007 PubMed Central PMCID 2007 to 2007 PubMed Central PMCID 2003 to 2003 The Second University of Medical Science 2000 to 2002
Lecturer of Chemistry Department of Chemistry, Norman Bethune University - Changchun, CN 1994 to 2000
Lecturer of Chemistry
Education:
Northeast Normal University
BS in Chemistry
Hongjun Zhang Photo 22

Hongjun Zhang

Publications & IP owners

Us Patents

Cycloalkyl-Fused Tetrahydroquinolines As Crthreceptor Modulators

US Patent:
8592383, Nov 26, 2013
Filed:
Jun 14, 2012
Appl. No.:
13/523354
Inventors:
Xianhai Huang - Warren NJ, US
Jason Brubaker - Cambridge MA, US
Scott L. Peterson - Salem MA, US
John W. Butcher - Berlin MA, US
Joshua T. Close - Franklin MA, US
Michelle Martinez - Medford MA, US
Rachel Nicola MacCoss - Oxford, GB
Joon O. Jung - Newton MA, US
Phieng Siliphaivanh - Newton MA, US
Hongjun Zhang - Newton MA, US
Robert G. Aslanian - Rockaway NJ, US
Purakkattle Johny Biju - Piscataway NJ, US
Li Dong - Roselle Park NJ, US
Ying Huang - Berkeley Heights NJ, US
Kevin D. McCormick - Basking Ridge NJ, US
Anandan Palani - Bridgewater NJ, US
Ning Shao - Watchung NJ, US
Wei Zhou - Scotch Plains NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 221/16
C07D 401/10
C07D 413/10
A61K 31/473
A61K 31/501
A61K 31/506
A61K 31/5377
A61K 31/706
A61P 11/00
A61P 11/06
A61P 37/08
C07H 15/26
US Classification:
514 32, 51421018, 5142328, 51425204, 514256, 514290, 536 174, 544126, 544238, 544335, 546 79
Abstract:
The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I),.

Quinazolinone-Type Compounds As Crth2 Antagonists

US Patent:
2013021, Aug 15, 2013
Filed:
Oct 6, 2011
Appl. No.:
13/878654
Inventors:
Robert G. Aslanian - Rockaway NJ, US
Christopher W. Boyce - Flemington NJ, US
Brian A. McKittrick - New Vernon NJ, US
Kevin D. McCormick - Basking Ridge NJ, US
Anandan Palani - Bridgewater NJ, US
Jun Qin - Somerset NJ, US
Haiqun Tang - Belle Mead NJ, US
Dong Xiao - Warren NJ, US
Younong Yu - East Brunswick NJ, US
John P. Caldwell - Ringwood NJ, US
Elizabeth Helen Kelley - Lynnfield MA, US
Hongjun Zhang - Newton MA, US
Phieng Siliphaivanh - Newton MA, US
Rachel N. MacCoss - Oxford, GB
Joey L. Methot - Westwood MA, US
Jolicia Polivina Gauuan - Schenectady NY, US
Qin Jiang - Latham NY, US
Andrew J. Leyhane - Latham NY, US
Johny Biju - Piscataway NJ, US
Li Dong - Lawrenceville NJ, US
Xian Huang - Warren NJ, US
Ning Shao - Watchung NJ, US
Wei Zhou - Scotch Plains NJ, US
Pawan K. Dhondi - Elizabeth NJ, US
International Classification:
C07D 239/91
A61K 31/517
A61K 45/06
C07D 403/10
C07D 417/10
C07D 413/10
C07D 405/10
C07D 413/14
C07D 498/10
C07D 403/14
A61K 31/55
C07D 401/14
A61K 31/5395
C07D 471/04
C07D 401/10
US Classification:
51421207, 544284, 51426621, 5142662, 51426623, 544290, 51426624, 5142663, 544230, 540523, 514249, 544 66, 5142292, 51426622
Abstract:
This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTHreceptor.

Quinoxalines And Aza-Quinoxalines As Crth2 Receptor Modulators

US Patent:
2013030, Nov 14, 2013
Filed:
Dec 19, 2011
Appl. No.:
13/996361
Inventors:
Christopher W. Boyce - Flemington NJ, US
Sylvia Joanna Degrado - Scotch Plains NJ, US
Xiao Chen - Edison NJ, US
Jun Qin - Edison NJ, US
Younong Yu - East Brunswick NJ, US
Kevin D. McCormick - Basking Ridge NJ, US
Anandan Palani - Bridgewater NJ, US
Dong Xiao - Warren NJ, US
Robert George Aslanian - Rockaway NJ, US
Jie Wu - Scotch Plains NJ, US
Ashwin Umesh Rao - Morganville NJ, US
Phieng Siliphaivanh - Newton MA, US
Joey L. Methot - Westwood MA, US
Hongjun Zhang - Newton MA, US
Elizabeth Helen Kelley - Lynnfield MA, US
William Colby Brown - Cleveland Heights OH, US
Qin Jiang - Latham NY, US
Jolicia Polivina Gauuan - Schenectady NY, US
Andrew J. Leyhane - Latham NY, US
Purakkattle Johny Biju - Piscataway NJ, US
Pawan K. Dhondi - Elizabeth NJ, US
Li Dong - Lawrenceville NJ, US
Salem Fevrier - Cranford NJ, US
Xianhai Huang - Warren NJ, US
Henry M. Vaccaro - South Plainfield NJ, US
International Classification:
C07D 241/42
C07D 401/12
C07D 403/06
C07D 471/04
A61K 31/4985
C07D 471/10
C07D 405/12
C07D 401/14
A61K 31/506
A61K 31/55
C07D 417/12
C07D 498/04
C07D 491/107
A61K 45/06
A61K 31/498
US Classification:
51421018, 544353, 514249, 544350, 544230, 51421021, 544295, 540523, 51421207
Abstract:
The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction.

Rorgammat Inhibitors

US Patent:
2014003, Feb 6, 2014
Filed:
Feb 10, 2012
Appl. No.:
13/983818
Inventors:
Willem Frederik Johan Karstens - Berghem, NL
Mario Van Der Stelt - Utrecht, NL
Jos Cals - Oss, NL
Rita Corte Real Goncalves Azevedo - 's-Hertogenbosch, NL
Kenneth Jay Barr - Boston MA, US
Hongjun Zhang - Newton MA, US
Richard Thomas Beresis - Shanghai, CN
Dongshan Zhang - Shanghai, CN
Xiaobang Duan - Shanghai, CN
Assignee:
Merck Sharp & Dohme B.V. - Haarlem
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/4439
A61K 31/416
C07D 471/04
A61K 31/437
A61K 45/06
C07D 401/12
A61K 31/4709
C07D 413/12
A61K 31/4245
C07D 231/56
C07D 401/06
US Classification:
51421021, 5483625, 514406, 546120, 514303, 546113, 514300, 5462757, 514338, 546172, 514314, 548126, 514364
Abstract:
The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or condition.

Novel Substituted Tetrahydroquinolin Compounds As Indoleamine 2,3-Dioxygenase (Ido) Inhibitors

US Patent:
2022023, Jul 28, 2022
Filed:
Jun 8, 2020
Appl. No.:
17/615718
Inventors:
Yongxin HAN - Boston MA, US
Yongqi DENG - Newton MA, US
Hua ZHOU - Boston MA, US
Meredeth A. MCGOWAN - Boston MA, US
Hongjun ZHANG - Boston MA, US
Wensheng YU - Kenilworth NJ, US
Brett A. HOPKINS - Boston MA, US
Xavier FRADERA - Boston MA, US
Nunzio SCIAMMETTA - Boston MA, US
- Rahway NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 401/06
C07D 401/08
C07D 471/04
C07D 519/00
Abstract:
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Novel Substituted Tricyclic Compounds As Indoleamine 2,3-Dioxygenase Inhibitors

US Patent:
2021040, Dec 30, 2021
Filed:
Nov 1, 2019
Appl. No.:
17/289062
Inventors:
- Rahway NJ, US
David Jonathan Bennett - Winchester MA, US
Indu Bharathan - Somerville MA, US
Liangqin Guo - Monroe Township NJ, US
Brett A. Hopkins - Brownsburg IN, US
Xianhai Huang - Warren NJ, US
Derun Li - West Roxbury MA, US
Min Lu - Brookline MA, US
Alexander Pasternak - Jamaica Plain MA, US
David L. Sloman - Newton MA, US
Hongjun Zhang - Boston MA, US
Hua Zhou - Acton MA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 471/04
C07D 401/04
C07D 215/14
C07D 209/94
C07D 403/04
Abstract:
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Novel [1.1.1] Bicyclo Compounds As Indoleamine 2,3-Dioxygenase Inhibitors

US Patent:
2021039, Dec 23, 2021
Filed:
Apr 15, 2019
Appl. No.:
17/047247
Inventors:
- Rahway NJ, US
Hongjun Zhang - Boston MA, US
Ping Chen - Edison NJ, US
Dane Clausen - Rahway NJ, US
Xavier Fradera - Boston MA, US
Yongxin Han - Needham MA, US
Shuwen He - Fanwood NJ, US
Xianhai Huang - Warren NJ, US
Alexander Pasternak - Jamaica Plain MA, US
Qinglin Pu - Needham MA, US
Li Xiao - Cranbury NJ, US
Feng Ye - Scotch Plains NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/44
A61K 45/06
C07C 237/22
C07C 255/60
C07D 213/75
C07C 271/36
C07C 233/78
C07C 271/24
C07C 233/79
C07D 213/81
C07D 271/06
C07D 239/28
C07D 215/48
C07C 275/30
C07C 275/28
C07D 239/42
C07D 305/06
C07D 261/08
C07D 471/04
C07D 261/20
C07D 209/34
C07D 277/56
C07D 217/02
C07D 231/14
C07D 237/28
C07D 241/24
C07D 217/26
A61K 31/167
A61K 31/27
A61K 31/4245
A61K 31/47
A61K 31/17
A61K 31/505
A61K 31/337
A61K 31/437
A61K 31/42
A61K 31/426
A61K 31/472
A61K 31/415
A61K 31/4965
Abstract:
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Novel Substituted Tetrahydroquinoline Compounds As Indoleamine 2,3-Dioxygenase Inhibitors

US Patent:
2021016, Jun 3, 2021
Filed:
Aug 12, 2019
Appl. No.:
17/267866
Inventors:
- Rahway NJ, US
Xavier Fradera - Brookline MA, US
Yongxin Han - Needham MA, US
Alexander Pasternak - Jamaica Plain MA, US
Li Xiao - Cranbury NJ, US
Hongjun Zhang - Boston MA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/506
A61K 45/06
C07D 215/20
C07D 401/12
C07D 401/04
A61K 31/47
A61K 31/4709
Abstract:
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Possible Relatives

David Zhang  Dawei Zhang  Dazhi Zhang  De K Zhang  Da Q Zhang  Dachuan Zhang  Daijun Zhang  Hongjun Liu 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.